BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30635159)

  • 1. Final results of the phase 1/2, open-label clinical study of intravenous recombinant human N-acetyl-α-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB.
    Whitley CB; Vijay S; Yao B; Pineda M; Parker GJM; Rojas-Caro S; Zhang X; Dai Y; Cinar A; Bubb G; Patki KC; Escolar ML
    Mol Genet Metab; 2019 Feb; 126(2):131-138. PubMed ID: 30635159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
    Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
    Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
    Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial.
    Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Bhargava P; Kerr D; Alexanderian D
    Mol Genet Metab; 2019 Feb; 126(2):121-130. PubMed ID: 30528227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
    Tardieu M; Zérah M; Gougeon ML; Ausseil J; de Bournonville S; Husson B; Zafeiriou D; Parenti G; Bourget P; Poirier B; Furlan V; Artaud C; Baugnon T; Roujeau T; Crystal RG; Meyer C; Deiva K; Heard JM
    Lancet Neurol; 2017 Sep; 16(9):712-720. PubMed ID: 28713035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
    Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
    J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
    Yogalingam G; Luu AR; Prill H; Lo MJ; Yip B; Holtzinger J; Christianson T; Aoyagi-Scharber M; Lawrence R; Crawford BE; LeBowitz JH
    PLoS One; 2019; 14(1):e0207836. PubMed ID: 30657762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
    Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
    Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose genistein in Sanfilippo syndrome: A randomised controlled trial.
    Ghosh A; Rust S; Langford-Smith K; Weisberg D; Canal M; Breen C; Hepburn M; Tylee K; Vaz FM; Vail A; Wijburg F; O'Leary C; Parker H; Wraith JE; Bigger BW; Jones SA
    J Inherit Metab Dis; 2021 Sep; 44(5):1248-1262. PubMed ID: 34047372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Whitley CB; Muenzer J; Gasperini S; Del Toro M; Muschol N; Cleary M; Sevin C; Shapiro E; Alexanderian D
    Mol Genet Metab; 2021; 134(1-2):175-181. PubMed ID: 34247932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.
    Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A
    Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Processing of mutant N-acetyl-α-glucosaminidase in mucopolysaccharidosis type IIIB fibroblasts cultured at low temperature.
    Meijer OLM; Te Brinke H; Ofman R; IJlst L; Wijburg FA; van Vlies N
    Mol Genet Metab; 2017 Sep; 122(1-2):100-106. PubMed ID: 28751108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.
    Meijer OLM; Welling L; Valstar MJ; Hoefsloot LH; Brüggenwirth HT; van der Ploeg AT; Ruijter GJG; Wagemans T; Wijburg FA; van Vlies N
    J Inherit Metab Dis; 2016 May; 39(3):437-445. PubMed ID: 26907177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B.
    Muschol N; Koehn A; von Cossel K; Okur I; Ezgu F; Harmatz P; de Castro Lopez MJ; Couce ML; Lin SP; Batzios S; Cleary M; Solano M; Nestrasil I; Kaufman B; Shaywitz AJ; Maricich SM; Kuca B; Kovalchin J; Zanelli E
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36413418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B.
    Grover A; Crippen-Harmon D; Nave L; Vincelette J; Wait JCM; Melton AC; Lawrence R; Brown JR; Webster KA; Yip BK; Baridon B; Vitelli C; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Shaywitz AJ; Crawford BE; Fitzpatrick PA; LeBowitz JH; Bullens S; Aoyagi-Scharber M; Bunting S; O'Neill CA; Pinkstaff J; Bagri A
    Drug Deliv Transl Res; 2020 Apr; 10(2):425-439. PubMed ID: 31942701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B.
    Whitley CB; Cleary M; Eugen Mengel K; Harmatz P; Shapiro E; Nestrasil I; Haslett P; Whiteman D; Alexanderian D
    J Pediatr; 2018 Jun; 197():198-206.e2. PubMed ID: 29661560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
    Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
    Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
    Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
    Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.